• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly: December 2006 Issue

CenterWatch Monthly: December 2006 Issue

December 10, 2006
CenterWatch Staff

Increasing Minority Participation in Clinical Trials

Ensuring that clinical trial participation reflects the racial and ethnic makeup of the U.S. population and the epidemiology of the particular diseases being studied is becoming more of a priority for industry, government and academia. The barriers—while not insuperable—are numerous. Over-coming them will take a multi-pronged approach. One four-year research program undertaken last year by the Chronic Disease Prevention and Control Research Center at Baylor College of Medicine and the Intercultural Cancer Council and funded by Genentech is attempting to tackle the issue of increasing participation by underrepresented populations, including racial and ethnic minorities.

CROs Taking Tentative Steps Toward Reform

CROs have a big opportunity to help lead any changes in the drug development process in the wake of two high profile patient safety issues involving CROs in the past year. Despite the run of bad publicity, CROs seemed to have weathered the storm with strong revenues gains and share prices. But the CRO industry isn’t about to become complacent as it takes steps to carve out a leadership role in any reform efforts.

Mandatory GCP Certification in The Netherlands?

Nearly two years past the deadline, The Netherlands passed the EU Clinical Trial Directive into national law in March. Some are wasting no time in attempting to make certification in Good Clinical Practice (GCP) mandatory for clinical researchers who want to conduct a study in The Netherlands. It is a trend that could well gain traction throughout the EU.

Eye On: Skin Conditions

The skin is the largest and most exposed organ of the body, and, not surprisingly, it is prone to a variety of diseases. Hand dermatitis, or hand eczema, popularized in television commercials as “dishpan hands,” is one of the most common work-related diseases, affecting 5% to 10% of the population. It is characterized by hand rash, redness, dryness, cracking and inflammation.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing